Anglo American Plans to Oppose Any Appeal in Lead Poisoning Case
By Christian Moess Laursen
Anglo American said on Monday that it plans to oppose any appeal by the claimants in the Kabwe lead poisoning case.
The class action case is against the mining major's South African subsidiary Anglo American South Africa and brought on behalf of 140,000 Zambian children and women for alleged lead pollution. The multinational, diversified miner reiterated on Monday its stance that it isn't responsible for the alleged mass lead poisoning in Kabwe.
On Friday, the High Court of South Africa granted claimants the right to appeal against the prior High Court's decision to dismiss the case in December.
The court's latest decision doesn't undermine the prior judgment, Anglo American said.
In granting permission, the judge found that an appeal against the earlier decision had reasonable prospects of success on at least one ground of appeal, a statement on behalf of the claimants said.
The Kabwe claimants will now take their case against Anglo American South Africa before the Supreme Court of Appeal of South Africa later this year, it said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
April 22, 2024 03:48 ET (07:48 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom